Metabolic pathways involved in Xin-Ke-Shu protecting against myocardial infarction in rats using ultra high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 90, Issue , 2014, Pages 35-44

  Liu, Yue tao ^a   Jia, Hong mei ^a   Chang, Xing ^a   Cheng, Wei hua ^a   Zhao, Xin ^a   Ding, Gang ^a   Zhang, Hong wu ^a   Cai, Da yong ^a   Zou, Zhong Mei ^a  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

Author keywords

Metabolic pathways; Myocardial infarction; Pharmacological action; Plasma metabonomics; Xin Ke Shu

Indexed keywords

ARACHIDONIC ACID; CARDIOVASCULAR AGENT; CARNITINE; DOCOSAHEXAENOIC ACID; ISOPRENALINE; LEVACECARNINE; LINOLEIC ACID; PALMITOYLCARNITINE; PHYTOSPHINGOSINE; PROPRANOLOL; SPHINGANINE; SPHINGOLIPID; TRYPTOPHAN; TYRAMINE; UNCLASSIFIED DRUG; URIC ACID; XIN KE SHU;

AMINO ACID METABOLISM; ANIMAL MODEL; ARACHIDONIC ACID METABOLISM; ARTICLE; BIOCHEMISTRY; CHINESE MEDICINE; CONTROLLED STUDY; HEART INFARCTION; HEART INJURY; HEART PROTECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PURINE METABOLISM; QUADRUPOLE MASS SPECTROMETRY; QUADRUPOLE TIME OF FLIGHT MASS SPECTROMETRY; RAT; TIME OF FLIGHT MASS SPECTROMETRY; TRYPTOPHAN METABOLISM;

METABOLIC PATHWAYS; MYOCARDIAL INFARCTION; PHARMACOLOGICAL ACTION; PLASMA METABONOMICS; XIN-KE-SHU;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; ISOPROTERENOL; MALE; MASS SPECTROMETRY; MEDICINE, CHINESE TRADITIONAL; METABOLOMICS; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR;

EID: 84890222727     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2013.11.008     Document Type: Article

References (30)

1. Kulminski A.M., Culminskaya I., Arbeev K.G., Ukraintseva S.V., Stallard E., Arbeeva L., Yashin A.I. The role of lipid-related genes, aging-related processes, and environment in healthspan. Aging Cell 2013, 12:237-246.
2. Spite M., Serhan C.N. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ. Res. 2010, 107:1170-1184.
3. Kang Y.J. Herbogenomics: from traditional Chinese medicine to novel therapeutics. Exp. Biol. Med. (Maywood) 2008, 233:1059-1065.
4. Lu J.P., Yang J.O. Protective effect of Xin Ke Shu on myocardial ischemia and reperfusion injury. Med. J. Wuhan Univ. 2003, 24:254-257.
5. Peng J.B., Jia H.M., Liu Y.T., Zhang H.W., Dong S., Zou Z.M. Qualitative and quantitative characterization of chemical constituents in Xin-Ke-Shu preparations by liquid chromatography coupled with a LTQ Orbitrap mass spectrometer. J. Pharm. Biomed. Anal. 2011, 55:984-995.
6. Xu T., Peng J.B., Zhang W.T., Zhao X., Zhang T.T., Yang S.J., Fang L., Zou Z.M., Cai D.Y. Antiatherogenic and anti-ischemic properties of Traditional Chinese Medicine Xinkeshu via endothelial protecting function. Evid. Based Complement. Alternat. Med. 2012, 10.1155/2012/302137.
7. Zhang A.H., Sun H., Wang X.J. Recent advances in metabolomics in neurological disease, and future perspectives. Anal. Bioanal. Chem. 2013, 10.1007/s00216-013-7061-4.
8. Drexler D.M., Reily M.D., Shipkova P.A. Advances in mass spectrometry applied to pharmaceutical metabolomics. Anal. Bioanal. Chem. 2011, 399:2645-2653.
9. Wexler B.C., Greenberg B.P. Protective effects of clofibrate on isoproterenol-induced myocardial infarction in arteriosclerotic and non-arteriosclerotic rats. Atherosclerosis 1978, 29:373-395.
10. Zhang H.Y., Chen X., Hu P., Liang Q.L., Liang X.P., Wang Y.M., Luo G.A. Metabolomic profi{ligature}ling of rat serum associated with isoproterenol-induced myocardial infarction using ultra-performance liquid chromatography/time-of-flight mass spectrometry and multivariate analysis. Talanta 2009, 79:254-259.
11. Davies M.J. The pathology of myocardial ischaemia. J. Clin. Pathol. Suppl. (R. Coll. Pathol.) 1977, 30:45-52.
12. Yuan M., Breitkopf S.B., Yang X., Asara J.M. A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat. Protoc. 2012, 7:872-881.
13. Lopaschuk G.D., Gamble J. Acetyl-CoA carboxylase: an important regulator of fatty acid oxidation in the heart. Can. J. Physiol. Pharmacol. 1994, 72:1101-1109.
14. Ziadeh R., Hoffman E.P., Finegold D.N., Hoop R.C., Brackett J.C., Strauss A.W., Naylor E.W. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr. Res. 1995, 37:675-678.
15. Bene J., Komlósi K., Gasztonyi B., Juhász M., Tulassay Z., Melegh B. Plasma carnitine ester profile in adult celiac disease patients maintained on long-term gluten free diet. World J. Gastroenterol. 2005, 11:6671-6675.
16. Swirski F.K., Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013, 339:161-166.
17. Senn T., Hazen S.L., Tang W.H. Translating metabolomics to cardiovascular biomarkers. Prog. Cardiovasc. Dis. 2012, 55:70-76.
18. Hjelte L.E., Nilsson A. Arachidonic acid and ischemic heart disease. J. Nutr. 2005, 135:2271-2273.
19. Baylin A., Campos H. Arachidonic acid in adipose tissue is associated with nonfatal acute myocardial infarction in the central valley of Costa Rica. J. Nutr. 2004, 134:3095-3099.
20. Egom E.E., Mamas M.A., Clark A.L. The potential role of sphingolipid-mediated cell signaling in the interaction between hyperglycemia, acute myocardial infarction and heart failure. Expert Opin. Ther. Targets 2012, 16:791-800.
21. Greenberg A.J., Hackett S.R., Harshman L.G., Clark A.G. Environmental and genetic perturbations reveal different networks of metabolic regulation. Mol. Syst. Biol. 2011, 7:563.
22. Ohshita T., Nikawa T., Towatari T., Katunuma N. Effects of selective inhibition of cathepsin B and general inhibition of cysteine proteinases on lysosomal proteolysis in rat liver in vivo and in vitro. Eur. J. Biochem. 1992, 209:223-231.
23. Devika P.T., Prince P.S. Preventive effect of (-) epigallocatechin-gallate (EGCG) on lysosomal enzymes in heart and subcellular fractions in isoproterenol-induced myocardial infracted Wistar rats. Chem. Biol. Interact. 2008, 172:245-252.
24. Knapp F.F., Goodman M.M., Callahan A.P., Kirsch G. Radioiodinated 15-(p-iodophenyl)-3, 3-dimethylpentadecanoicacid: a useful new agent to evaluate myocardial fatty acid uptake. J. Nucl. Med. 1986, 27:521-531.
25. Tuunanen H., Knuuti J. Metabolic remodelling in human heart failure. Cardiovasc Res. 2011, 90:251-257.
26. Skak-Nielsen H., Torp-Pedersen C., Finer N., Caterson I.D., Van Gaal L., James W.P., Maggioni A.P., Sharma A.M., Coutinho W., Andersson C. Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. PLoS ONE 2013, 8:e59121.
27. Glantzounis G.K., Tsimoyiannis E.C., Kappas A.M., Galaris D.A. Uric acid and oxidative stress. Curr. Pharm. Des. 2005, 11:4145-4151.
28. Rapacciuolo A., Esposito G., Caron K., Mao L., Thomas S.A., Rockman H.A. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J. Am. Coll. Cardiol. 2001, 38:876-882.
29. Tan G.G., Lou Z.Y., Liao W.T., Dong X., Zhu Z.Y., Li W.H., Chai Y.F. Hydrophilic interaction and reversed-phase ultraperformance liquid chromatography TOF-MS for serum metabonomic analysis of myocardial infarction in rats and its applications. Mol. Biosyst. 2012, 8:548-556.
30. Shah S.H., Kraus W.E., Newgard C.B. Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. Circulation 2012, 126:1110-1120.